Detection kit for detecting lung cancer immune checkpoints by protein chip technology

Abstract

The invention discloses a detection kit for detecting lung cancer immune checkpoints by a protein chip technology, which comprises a solid protein, wherein the solid protein is subjected to surface cleaning and surface coating treatment, that is, (1) known immune checkpoints PD-1, PD-L1 and CTLA-4 protein receptors are fixed; (2) PD-1, PD-L1 and CTLA-4 in serum, plasma, lymph, percolate, cell solution and secretion, which are specifically bound with the biomolecules, of a patient to be detected are captured according to the characteristics of the biomolecules so as to enable the PD-1, PD-L1 and CTLA-4 to be fully subjected to antigen-antibody reaction; and (3) washing and purification are conducted, and then confirmation and biochemical analysis are carried out. The serum conditions of various antibodies can be detected only through one experiment, the detection kit has the advantages of being time-saving, efficient and high-throughput parallel detection and is the fruit of a modern immunology technology and a protein new material technology, the detection result can be qualitatively observed through naked eyes and can also be quantitatively detected through configuration of a reader, the result can be stored for a long time, and the detection kit has the effects of good repeatability, high stability and sensitivity and strong specificity.

Description

technical field [0001] The invention relates to the technical field of protein chip lung cancer immune detection, in particular to a protein chip technology detection kit for lung cancer immune checkpoint detection. Background technique [0002] T cells are the main effector cells in the tumor immune response. Under physiological conditions, the immune response of T cells is regulated by co-inhibitory molecules, namely immune checkpoints, to maintain tolerance to their own tissues, thereby avoiding the occurrence of autoimmune diseases. Co-stimulation The factor CD28 interacts with CD28 / CD86 on the surface of antigen-presenting cells, so that cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) transfers to the cell membrane, binds to CD28 / CD86 with a stronger binding force, and inhibits the growth of T cells. Activation and proliferation, programmed death receptor 1 (PD-1) is expressed in T cells, natural killer cells (NK), monocytes and B cells, and its function is similar...

AI Technical Summary

Problems solved by technology

[0004] 2. The Phase I clinical study of Nivolumab monotherapy for the first-line treatment of advanced NSCLC patients has also achieved certain results, but the recently announced Phase III clinical study (CheckMate-026) was declared a failure Reck and other clinical studies first confirmed the single drug of Pembrolizumab The effect of first-line treatment of advanced NSCLC is better than that of standard platinum-based double-drug chemotherapy, prompting the approval of Pembrolizumab by the US FDA and the European Union (EMA) for the treatment of PD-L1 high expression (TPS ≥ 50%), epidermal growth factor For metastatic NSCLC patients with negative EGFR and ALK mutations, Langer et al. showed that compared with chemotherapy alone, ORR and PFS were significantly improved in patients with lung cancer treated with Keytruda combined with chemotherapy. Based on this study, the US FDA accelerated approval of Keytruda combined with chemotherapy. Chemotherapy is the first-line treatment of metastatic non-squamous NSCLC. CTLA-4 representative inhibitors include Ipilimumab (MD*010) and Tremelimumad. The results of second-line treatment of Ipilimumab in phase II clinical studies of stage VI NSCLC suggest that this regimen can improve the PFS and OS of patients However, the interim analysis of the follow-up phase III clinical study did not show clinical benefit, so the study was terminated. In the NSCLC phase II clinical study of maintenance therapy after platinum-based chemotherapy, Tremelimumad could not prolong the PFS of patients

[0006] Combined with the above from second-line treatment to first-line treatment to combined treatment, immune checkpoint inhibitor therapy has gradually improved the treatment effect of lung cancer, and is reforming the treatment strategy of lung cancer. However, only a small number of patients can apply this immunotherapy at present, and it is used blindly It will significantly increase the incidence of adverse reactions and accelerate the malignant process of patients

The reason is that so far, there is no effective detection method that can detect the content of PD-1, PD-L1, and CTLA-4 in the blood of a single individual tumor patient, so as to infer whether the patient is healthy or not. Immune checkpoint inhibitor drug works

Images